Proshares Pet Care ETF

National Advertising Review Board Refers Merck's Bravecto Dose Claim to FTC and FDA

Merck and Kailun Bio's Sac-TMT Succeeds in Phase III Endometrial Cancer Trial

French Anti-Fraud Officials Raid Nestle's Perrier Plant Amid Fraud Probe

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

FactSet Survey: Analysts Cut ZTS Median Price Target to $117

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Freshpet CEO William B. Cyr Sells 42,497 Shares for $2.07 Million

Allworth Financial LP Increases Merck Holdings by 71.4%

Amundi Increases Stake in Merck Above 3% Threshold

Merck Shows Latest Progress in Its Oncology Portfolio

Merck Unaffected by Daiichi Sankyo's Updated Antibody-Drug Conjugate Supply Plan

Zoetis released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 2.262 B (forecast USD 2.301 B), actual EPS USD 1.42 (forecast USD 1.5366)

Zoetis Reports Q1 2026 Earnings

Zoetis Reports Q1 Earnings Per Share of $1.42

Freshpet released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 297.64 M (forecast USD 291.53 M), actual EPS USD 0.9053 (forecast USD 0.0886)

Jefferies Reiterates Buy Rating on IDEXX Laboratories

World Investment Advisors Increased Holdings in Merck in Q4

Freshpet Raises 2026 Sales Growth Guidance to 8%-11%

Pictet 大幅减持 Chewy 股票

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

MetaVia

Vida Global

Micware

BiomX

Tradr 2X Long XNDU Daily ETF

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

LABU

PAWZ

ARKG

The CEO of Zoetis informed investors that the overall economic conditions would see a gradual enhancement, projecting a 3% to 5% increase in organic revenue for the fiscal year 2026. However, this optimistic guidance was contradicted when the company reduced its forecast shortly after, leading to a significant stock drop where shares plummeted by 20%. This event occurred in New York on May 20, 2026, impacting investors in Zoetis Inc. (NYSE: ZTS).

Unusual Whales

Zoetis

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VG Health

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

iShares Global Healthcare

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

ZTS Investor Alert: Levi & Korsinsky Investigates Zoetis (ZTS) for Potential Securities Fraud

MNDY

Investors are focusing on quarterly earnings for stock picks. Wix (WIX) hit a 52-week low, facing short selling due to AI competition. Monday (MNDY) reported $49 million in Q1 operating profit, with Q2 revenue guidance up to $356 million. Zoetis (ZTS) also reached a 52-week low, with a 10% growth in international revenue but an 8% decline in the U.S. market. Caution is advised for drug stocks as inflation impacts pet care spending.

Baystreet

Wix.com

Monday.com

Weekly Stock Picks Starting on May 19, 2026

On May 12, MICHAEL MCCALLISTER, Director at Zoetis, purchased 3,000 shares worth $233,273, indicating confidence in the company. Despite this, Zoetis shares fell by 1.63% to $75.69. The company, which specializes in animal health products, reported a revenue growth of 2.91% but has a low gross margin of 71.66% and a high debt-to-equity ratio of 2.86. Its current P/E ratio of 12.61 suggests potential undervaluation. Insider transactions are important for investors but should be part of a broader analysis.

benzinga_article

Pfizer

Major Purchase Alert: MICHAEL MCCALLISTER Invests $233K In Zoetis Stock

Ademi LLP is investigating potential securities fraud claims against Zoetis Inc. (NYSE: ZTS) due to possible inaccuracies in the company's financial statements and business operations. This follows Zoetis's acknowledgment of reduced customer spending on non-emergency pet healthcare treatments. The investigation is open to shareholders, with no cost or obligation to participate.

prnewswire

21:56 ETShareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Zoetis Inc.

Shares of Zoetis (NYSE: ZTS) fell 20% after the company reported Q1 sales growth of 3% and adjusted earnings per share growth of 9%, both below analysts' expectations. The company's weak guidance for 2026 indicates that pet owners may be more price-sensitive, impacting demand for premium products. Additionally, an 8% decline in U.S. pet healthcare sales suggests a shift in consumer spending behavior. Despite growth in livestock and international sales, Zoetis faces challenges ahead and will need to innovate to drive future growth.

nasdaq

NVIDIA

Intel

Netflix

S&P 500

Nasdaq

NVIDIA Corporation

Why Zoetis Shares Plummeted Today

Zoetis, Inc. (ZTS) shares fell 12.8% after the company revised its fiscal 2026 outlook, projecting earnings between $6.35 and $6.50 per share, down from previous estimates. Despite a slight increase in Q1 net income to $601 million ($1.42 per share), adjusted earnings rose to $1.53 per share. Revenue for the quarter increased 3% to $2.26 billion, but organic revenue growth was flat. The stock is currently trading at $96.99, reflecting a significant drop in pre-market trading.

rttnews

Zoetis Shares Plunge 12.8% As FY26 Outlook Slashed; Q1 EPS Rises

CENTA

CENT

Central Garden & Pet (NASDAQ:CENT) reported quarterly earnings of $1.29 EPS, exceeding estimates of $1.08. Revenue reached $906.15 million, surpassing expectations of $846.58 million, marking an 8.7% increase year-over-year. The company updated its FY 2026 EPS guidance to $2.70. Central's strong liquidity includes $653 million in cash, supporting future growth and M&A. Shares rose to $36.83, with a market cap of $2.29 billion. Insider trading included significant sales by directors, while institutional investors increased their stakes in the company.

Market Beat

Central Garden & Pet

NASDAQ Composite Index

UBS Group AG

Central Garden & Pet (NASDAQ:CENT) Releases Earnings Results

U.S. pet ownership has increased by over 8% since 2016, reaching 77.5 million households. The American Veterinary Medical Association (AVMA) celebrates National Pet Week (May 3-9) to promote the human-animal bond and encourage responsible pet ownership. This year's theme, "Happiness is a Healthy Pet," emphasizes the importance of regular veterinary care, nutrition, and exercise. The AVMA provides resources for pet owners to ensure their pets' health and well-being, with daily topics focusing on pet selection, behavioral health, nutrition, veterinary visits, safe travel, emergency preparedness, and senior pet care.

15:56 ETNational Pet Week 2026: Pet ownership surges as AVMA celebrates human-animal bond

Shares of Zoetis Inc. (ZTS) fell 2.42% to $113.83 on Wednesday, marking its second consecutive day of losses. The stock is now 33.91% below its 52-week high of $172.23. In comparison, Merck & Co. Inc. (MRK) rose 0.84%, while IDEXX Laboratories Inc. (IDXX) dropped 2.58%. The overall market was also down, with the S&P 500 Index falling 0.04% and the Dow Jones Industrial Average down 0.57%. Trading volume was below the 50-day average.

MarketWatch Automated

Dow Jones Industrial Average

Merck

IDEXX Labs

Zoetis Inc. Stock Underperforms Wednesday When Compared To Competitors

Shares of Zoetis Inc. (ZTS) fell 1.24% to $116.06 on Thursday, marking the third consecutive day of losses amid a declining stock market. The S&P 500 Index and Dow Jones Industrial Average also experienced losses. Zoetis is currently 32.61% below its 52-week high of $172.23. In comparison, Merck & Co. Inc. rose 1.53%, while IDEXX Laboratories Inc. dropped 3.01%. Trading volume for Zoetis was 4.5 million, surpassing its 50-day average of 4.1 million.

Zoetis Inc. Stock Underperforms Thursday When Compared To Competitors

Proshares Pet Care ETF(PAWZ.US)